A detailed history of Round Rock Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Round Rock Advisors, LLC holds 360 shares of REGN stock, worth $272,451. This represents 0.09% of its overall portfolio holdings.

Number of Shares
360
Previous 360 -0.0%
Holding current value
$272,451
Previous $378,000 -0.0%
% of portfolio
0.09%
Previous 0.09%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$883.2 - $1071.19 $7,065 - $8,569
-8 Reduced 2.17%
360 $378,000
Q1 2024

Apr 24, 2024

SELL
$902.69 - $993.35 $83,047 - $91,388
-92 Reduced 20.0%
368 $354,000
Q2 2023

Jul 20, 2023

BUY
$700.03 - $830.35 $70,003 - $83,035
100 Added 27.78%
460 $330,000
Q4 2022

Jan 19, 2023

SELL
$705.89 - $766.39 $7,058 - $7,663
-10 Reduced 2.7%
360 $0
Q2 2022

Jul 22, 2022

BUY
$548.35 - $738.84 $202,889 - $273,370
370 New
370 $219,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Round Rock Advisors, LLC Portfolio

Follow Round Rock Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Round Rock Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Round Rock Advisors, LLC with notifications on news.